Cargando…

Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques

BACKGROUND: Topically delivered tenofovir (TFV) from intravaginal rings, tablets, or gels is being evaluated for HIV prevention. We previously demonstrated that TFV delivered vaginally by gel protected macaques from vaginal infection with SHIV. Here we investigated efficacy of the TFV gel against va...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dobard, Charles W, Sharma, Sunita, Cong, Mian-er, West, Rolieria, Makarova, Natalia, Holder, Angela, Pau, Chou-Pong, Hanson, Debra L., Novembre, Francis J, Garcia-Lerma, Jose Gerardo, Heneine, Walid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4528693/ https://www.ncbi.nlm.nih.gov/pubmed/26253002 http://dx.doi.org/10.1186/s12977-015-0195-z

Ejemplares similares

Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir
por: García-Lerma, J. Gerardo, et al.
Publicado: (2008)

Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques
por: Dobard, Charles W., et al.
Publicado: (2022)

Antiretroviral Drug Activity in Macaques Infected during Pre-Exposure Prophylaxis Has a Transient Effect on Cell-Associated SHIV DNA Reservoirs
por: Cong, Mian-er, et al.
Publicado: (2016)

Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaques
por: Makarova, Natalia, et al.
Publicado: (2022)

The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques
por: Daly, Michele B., et al.
Publicado: (2020)

Prevention of Vaginal SHIV Transmission in Macaques by a Coitally-Dependent Truvada Regimen
por: Radzio, Jessica, et al.
Publicado: (2012)

Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis
por: Zheng, Qi, et al.
Publicado: (2012)

Comparative Pharmacokinetics and Local Tolerance of Tenofovir Alafenamide (TAF) From Subcutaneous Implant in Rabbits, Dogs, and Macaques
por: Gatto, G. J., et al.
Publicado: (2022)

Topical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-Intravaginal Rings Protects Macaques from Multiple SHIV Exposures
por: Srinivasan, Priya, et al.
Publicado: (2016)

Development of a repeat-exposure penile SHIV infection model in macaques to evaluate biomedical preventions against HIV
por: Garber, David A., et al.
Publicado: (2018)

Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection
por: Bekerman, Elena, et al.
Publicado: (2020)

Brief Report: HIV-1 Evolution in Breakthrough Infections in a Human Trial of Oral Pre-exposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate
por: Ruone, Susan, et al.
Publicado: (2016)

Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection
por: Radzio-Basu, Jessica, et al.
Publicado: (2019)

Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection
por: Van Rompay, Koen KA, et al.
Publicado: (2007)

T Cell Chemo-Vaccination Effects after Repeated Mucosal SHIV Exposures and Oral Pre-Exposure Prophylaxis
por: Kersh, Ellen N., et al.
Publicado: (2011)

Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection
por: Young, Isabella C., et al.
Publicado: (2023)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

Ganciclovir–tenofovir interaction leading to tenofovir-induced nephrotoxicity
por: Soanker, Radhika, et al.
Publicado: (2014)

Population pharmacokinetics of tenofovir and tenofovir‐diphosphate in healthy women
por: Burns, Rebecca N., et al.
Publicado: (2015)

Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings
por: Thurman, Andrea Ries, et al.
Publicado: (2019)

Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide
por: Lalley-Chareczko, Linden, et al.
Publicado: (2020)

Review of tenofovir-emtricitabine
por: Masho, Saba Woldemichael, et al.
Publicado: (2007)

Chemoenzymatic Synthesis of Tenofovir
por: Zdun, Beata, et al.
Publicado: (2023)

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
por: Funderburg, Nicholas T., et al.
Publicado: (2016)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
por: Michienzi, Sarah M, et al.
Publicado: (2021)

Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients
por: Seo, Jun-Won, et al.
Publicado: (2020)

Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing
por: Johnson, Kelly A, et al.
Publicado: (2021)

Single oral dose for HIV pre or post-exposure prophylaxis: user desirability and biological efficacy in macaques
por: Massud, Ivana, et al.
Publicado: (2020)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
por: Hill, Andrew, et al.
Publicado: (2018)

Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity
por: Walti, Laura N, et al.
Publicado: (2018)

Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate
por: Huhn, Gregory D, et al.
Publicado: (2019)

Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects
por: Lee, Sangmi, et al.
Publicado: (2021)

Adherence Predictors in Pregnant Women Living with HIV on Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate
por: Eke, Ahizechukwu C
Publicado: (2022)

Development, Characterization and In Vivo Pharmacokinetic Assessment of Rectal Suppositories Containing Combination Antiretroviral Drugs for HIV Prevention
por: Jhunjhunwala, Kunal, et al.
Publicado: (2021)

Tenofovir Nephrotoxicity: 2011 Update
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2011)

Tenofovir and Severe Symptomatic Hypophosphatemia
por: Kichloo, Asim, et al.
Publicado: (2019)

Investigating Organ Toxicity Profile of Tenofovir and Tenofovir Nanoparticle on the Liver and Kidney: Experimental Animal Study
por: Peter, Aniekan Imo, et al.
Publicado: (2018)

Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide
por: Dickson, Sean, et al.
Publicado: (2022)

96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients
por: Liu, Zhihong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ts0l46cjgptb9ls50182dgrsl0